IRVINE, CA--(Marketwired - Nov 30, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Honorable Judge Kimberly Mueller, appointed to the bench by former President Barack Obama, set the hearing on the temporary restraining order for today, Thursday, November 30, 2017 at 3:30pm in Department 3 of the US District Courthouse, located at 501 "I" Street, #4200 in Sacramento, California. The hearing is public and anyone interested may attend.
On October 27, 2017, Cannabis Science, Inc. (the "Company"), along with its partners Winnemucca Shosoni MBS, American States University, Free Spirit Organics NAC and HRM Farms filed a Complaint in the U.S. District Court for the Eastern District of California against ten San Joaquin County defendants including the Board of Supervisors, County Counsel; District Attorney and the Sheriff and against the federal Drug Enforcement Agency.
The Complaint stems from a search warrant and subject seizure executed by the Defendants on the Plaintiff's 26.19-acre plot of land where it was growing industrial hemp. On November 17, 2017, CSI and the rest of the plaintiffs filed seven documents including 45 pages of pleadings, seven declarations, and 150 pages of exhibits asking the Court to issue a temporary restraining order.
Recently, the Plaintiffs learned the DEA was not involved and dismissed it. It had been surprising to discover evidence of DEA involvement at the outset because plaintiffs believed they had been operating with the blessing of the DEA. Accordingly Plaintiffs were pleased to learn that the DEA was not involved with the subject seizure and was apparently unconcerned with the industrial hemp research project.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer (CMO)
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder